Piramal Imaging & IBA molecular sign global agreement

Piramal Imaging SA and IBA Molecular have announced an agreement whereby IBA Molecular will manufacture and distribute 18F-Florbetaben in the European and US markets. 18 F – Florbetaben is a radiopharmaceutical currently in development for use with positron emission tomography for the detection of beta-Amyloid plaque deposition in the brain, a pathological feature associated with Alzheimer’s disease and other neurologic conditions.

“We are committed to creating a strong global pharma business based on intellectual property. 18F-Florbetaben is our lead compound in the molecular imaging business, and we are confident that it has the potential to increase clinicians’ accuracy and confidence. Piramal and IBA Molecular share a common vision and dedication towards fulfilling unmet medical needs and investing in superior discovery and research,” said Ajay Piramal, Chairman, Piramal Group.

“IBA Molecular is deeply committed to the future of nuclear medicine, and the 18F-Florbetaben distribution agreement with Piramal will allow us to provide, upon its approval, one of the most anticipated compounds in nuclear medicine to our network of customers. We have seen data from the global phase III results of 18F-Florbetaben, and recognize the significant potential of this compound. We are looking forward to joining forces with the Piramal team in their worldwide launch of the product,” said Renaud Dehareng, Chief Executive Officer of IBA Molecular.

Piramal recently acquired the intellectual property and worldwide development, marketing and distribution rights of the lead compound 18F-Florbetaben as well as other clinical and pre-clinical assets of Bayer Healthcare’s molecular imaging business to form its imaging subsidiary, Piramal Imaging SA.